Medtronic's MiniMed Exchange Window Closes as Barclays Initiates Coverage at Equal-Weight

Barclays initiated Medtronic at Equal-Weight with a $95 price target as the MiniMed exchange ratio was locked in and the tender offer closed Friday.

Barclays analyst Christopher Pasquale kicked off coverage of Medtronic on Tuesday with an Equal-Weight rating and a $95 price target, giving investors a fresh reference point just as the medical device maker wraps up one of the more consequential portfolio moves in its recent history.

The stock finished the week on a firm note in European trading, closing Friday at EUR 79.00 for a gain of 1.0%. Over the trailing seven sessions, the shares have added 3.0%, a stretch that coincided with both the analyst launch and the final stages of the MiniMed separation.

Exchange Ratio Locked In

Medtronic set the definitive exchange ratio for its diabetes spinoff at 4.5939 MiniMed shares for every Medtronic share tendered, a figure confirmed on Wednesday. The offer covered as many as 225,361,295 MiniMed shares, with an over-allotment option for an additional 27,452,053 shares should demand exceed the base amount.

A Thursday update to the offering documents put the exchange into sharper terms: full subscription would mean roughly 49,056,639 Medtronic shares being accepted, while tapping the entire over-allotment reserve would lift that figure to about 55,032,401 of the company's own shares. The tender window ran out at the close of business on Friday, moving the diabetes unit's carve-out into its decisive phase and giving Medtronic room to sharpen its capital allocation.

Research Spending and Regulatory Wins Pile Up

Supporting the operational side of the story, Medtronic disclosed in its Impact Report for fiscal 2026 that it plowed $2.9 billion into research and development during the period. The company also notched more than 315 product approvals across key markets and reached over 82 million patients worldwide.

Cardiology delivered one of the more visible wins back on September 30, when the FDA cleared the Affera Prism-2 Mapping software, which picked up its European CE mark at the same time. Medtronic also secured CE certification for the PulseSelect ProxBox Adapter and its accompanying software.

The surgical and interventional segments have been moving in step. On Wednesday, the FDA granted 510(k) clearance for navigated ApexCut EM blades used in sinus procedures, tools that link powered surgical instruments directly to the company's Stealth AXiS ENT navigation platform.

Clinical Data and a New Reimbursement Landscape

Fresh study results have added to the pipeline narrative. On October 3, at the VEINS 2026 specialist conference, Medtronic presented findings from its global VenaSeal Spectrum program, which examines use of the technology in advanced chronic venous disease. Two days earlier, on Tuesday, the company released exploratory 24-month data from the TITAN 2 trial of its Altaviva system, showing a sustained reduction in nocturia episodes among treated patients. Ariana L. Smith was named national principal investigator for ENDURANCE, the post-approval follow-up study.

Reimbursement is shifting as well. As announced on October 1, the American Medical Association approved Category I CPT codes for both Altaviva and the Symplicity Spyral renal denervation system. Those billing codes take effect in January 2028, establishing a standardized foundation for future US reimbursement of the two therapies.